Introduction {#s1}
============

Liver cancer, which consists predominantly of hepatocellular carcinoma (HCC), was the sixth most common cancer worldwide and the third most common cause of cancer mortality in 2008 [@pone.0082773-Ferlay1]. In high-risk China, liver cancer was the third most common cancer with 402,000 new cases and the second most common cause of death from cancer with 372,000 deaths in 2008 [@pone.0082773-Li1]. Besides, HCC is the fastest growing cause of cancer-related deaths in men of USA [@pone.0082773-ElSerag1]. Thus, liver cancer is a serious fatal disease worldwide and has caused serious damage to human health. HCC accounts for about 90% of all primary liver cancers, and there are marked variations among geographic regions, racial, and ethnic groups, and between men and women [@pone.0082773-ElSerag2]. Most HCC cases (about 80%) occur in either sub-Saharan Africa or Eastern Asia, and China alone accounts for more than 50% of the world's cases [@pone.0082773-ElSerag2]. As a complex and multi-factorial process, hepatocellular carcinogenesis is still not fully understood [@pone.0082773-ElSerag2], [@pone.0082773-Dragani1]. Previous epidemiological studies have identified that major risk factors for the development of HCC are chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), liver cirrhosis, habitual alcohol abuse, and exposure to aflatoxin B1 [@pone.0082773-ElSerag2], [@pone.0082773-Dragani1]. However, most individuals with these known environmental risk factors never develop HCC while many HCC cases develop among individuals without those known risk factors, suggesting that genetic factors also play an important role in hepatocellular carcinogenesis [@pone.0082773-Dragani1].

TP53 is a tumour suppressor that plays an important role in cell cycle regulation and the maintenance of genome integrity [@pone.0082773-Tong1], [@pone.0082773-Hong1], [@pone.0082773-Marte1]. TP53 mediates the cellular response to DNA damage via effects on gene transcription, DNA synthesis and repair, genomic plasticity and apoptosis. Functional polymorphisms of the TP53 gene which influence the above activities of TP53 protein might be associated with human susceptibility to cancer. A common single nucleotide polymorphism in codon 72 of TP53 (rs1042522) causes the Arg to Pro amino acid substitution, and the 72Arg allele shows more efficient in inducing apoptosis [@pone.0082773-Bergamaschi1] and lower ability in inducing cell cycle arrest and DNA repair [@pone.0082773-Orsted1], [@pone.0082773-Siddique1]. In addition, the human homolog of mouse double minute 2 (MDM2), acting as a major negative regulator of the TP53 tumor suppressor protein, directly binds to the latter to inhibit its activity as a transcription factor, and ubiquitinates it enhancing its proteolytic breakdown [@pone.0082773-Bond1]. One polymorphism in the promoter region of MDM2, a T to G change at nucleotide 309 in the first intron (rs2279744), was associated with the enhanced MDM2 expression, and then attenuated function of the TP53 protein. Taken together, the two polymorphisms TP53 R72P and MDM2 SNP309 can accelerate carcinogenesis directly by affecting TP53 function and indirectly by down-regulation of TP53 via overexpression of MDM2, respectively. Hence, it is biologically reasonable to hypothesize a potential relationship between the TP53 R72P and MDM2 SNP309 polymorphisms and HCC risk.

Over the last two decades, a number of case--control studies have been conducted to investigate the associations between TP53 R72P and MDM2 SNP309 polymorphisms and HCC risk, but the results remain controversial and inconclusive. With respect to MDM2 SNP309 polymorphism, a meta-analysis by Ma et al. [@pone.0082773-Ma1] found that the MDM2 SNP309 polymorphism was associated with an increased HCC risk in Asians and Caucasians, however, they failed to include all eligible studies in the meta-analysis [@pone.0082773-Tomoda1], [@pone.0082773-Yang1], [@pone.0082773-Jiang1], which make their conclusions questionable. With respect to TP53 R72P polymorphism, two meta-analyses [@pone.0082773-Lv1], [@pone.0082773-Ding1] investigating the same hypothesis, quite similar in methods and performed almost at the same time, yielded different conclusions. Furthermore, the two previous meta-analyses did not cover all eligible studies. The exact relationship between genetic polymorphisms of TP53 R72P and MDM2 SNP309 and HCC susceptibility has not been entirely established. To provide the most comprehensive assessment of the associations between the TP53 R72P and MDM2 SNP309 polymorphisms and HCC risk, we performed an updated meta-analysis of all available studies. The meta-analysis presented in this study aims to assess whether TP53 R72P and MDM2 SNP309 polymorphisms associated with HCC risk and to investigate the possible combined effect between the MDM2 SNP309 and the TP53 R72P polymorphisms on HCC risk.

Methods {#s2}
=======

Search Strategy {#s2a}
---------------

This study was performed according to the proposal of Meta-analysis of Observational Studies in Epidemiology group (MOOSE) [@pone.0082773-Stroup1]. We conducted a comprehensive literature search in PubMed, Cochrane Library, Embase, and Chinese Biomedical Literature database (CBM) databases up to July 01, 2013 using the following search strategy: ("liver cancer", "hepatocellular carcinoma" or "HCC") and ("TP53", "P53", "codon 72", "Murine double minute 2", or "MDM2"). There was no restriction on time period, sample size, population, language, or type of report. All eligible studies were retrieved and their references were checked for other relevant studies. The literature retrieval was performed in duplication by two independent reviewers (Xue Qin and Qiliu Peng). When multiple publications reported on the same or overlapping data, we chose the most recent or largest population.

Selection Criteria {#s2b}
------------------

Studies included in the meta-analysis were required to meet the following criteria: (1) Case--control studies which evaluated the association between TP53 R72P and/or MDM2 SNP309 polymorphisms and HCC risk; (2) used an unrelated case--control design; (3) had an odds ratio (OR) with 95% confidence interval (CI) or other available data for estimating OR (95% CI); and (4) control population did not contain malignant tumor patients. Conference abstracts, case reports, editorials, review articles, and letters were excluded.

Data Extraction {#s2c}
---------------

Two investigators (Xue Qin and Qiliu Peng) independently extracted data from the eligible studies. Data extracted from eligible studies included the first author's name, publication date, country of origin, ethnicity, genotyping method, matching criteria, source of control, HCC confirmation, QC when genotyping, total numbers of cases and controls and genotype frequencies of cases and controls. The hepatitis virus infection status was additionally recorded for the stratified analysis. Two investigators checked the data extraction results and reached consensus on all of the data extracted.

Quality Score Assessment {#s2d}
------------------------

Methodological quality was independently assessed by two reviewers (Xue Qin and Qiliu Peng), according to a set of predefined criteria ([Table 1](#pone-0082773-t001){ref-type="table"}) based on the scale of Thakkinstian et al. [@pone.0082773-Thakkinstian1]. The revised criteria cover the credibility of controls, the representativeness of cases, assessment of HCC, genotyping examination, Hardy-Weinberg equilibrium (HWE) in the control population, and association assessment. A third reviewer (Shan Li) was invited to the discussion if disagreement still existed. Scores ranged from 0 (lowest) to 12 (highest). Articles with scores less than 8 were considered "low-quality" studies, whereas those with scores equal to or higher than 8 were considered "high-quality" studies.

10.1371/journal.pone.0082773.t001

###### Scale for quality assessment.

![](pone.0082773.t001){#pone-0082773-t001-1}

  Criteria                                                                                                                            Score
  ---------------------------------------------------------------------------------------------------------------------------------- -------
  Representativeness of cases                                                                                                        
  Selected from any population cancer registry                                                                                          2
  Selected from any gastroenterology/surgery service                                                                                    1
  Selected without clearly defined sampling frame or with extensive inclusion/exclusion criteria                                        0
  Credibility of controls                                                                                                            
  Population- or neighbor- based                                                                                                        3
  Blood donors or volunteers                                                                                                            2
  Hospital-based (cancer-free patients)                                                                                                 1
  Healthy volunteers, but without total description                                                                                    0.5
  Gastroenterology patients                                                                                                           0.25
  Not described                                                                                                                         0
  Ascertainment of hepatocellular carcinoma                                                                                          
  Histological or pathological confirmation                                                                                             2
  Diagnosis of hepatocellular carcinoma by patient medical record                                                                       1
  Not described                                                                                                                         0
  Genotyping examination                                                                                                             
  Genotyping done under "blinded" condition                                                                                             1
  Unblinded or not mentioned                                                                                                            0
  Hardy-Weinberg equilibrium                                                                                                         
  Hardy-Weinberg equilibrium in controls                                                                                                2
  Hardy-Weinberg disequilibrium in controls                                                                                             1
  No checking for Hardy-Weinberg disequilibrium                                                                                         0
  Association assessment                                                                                                             
  Assess association between genotypes and hepatocellular carcinoma with appropriate statistics and adjustment for confounders          2
  Assess association between genotypes and hepatocellular carcinoma with appropriate statistics without adjustment for confounders      1
  Inappropriate statistics used                                                                                                         0

Statistical Analysis {#s2e}
--------------------

Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated for each polymorphism in different comparison models, including allelic contrast, additive genetic models, recessive genetic model, and dominant genetic model.

The *Q* test and *I^2^* statistics were used to assess the statistical heterogeneity among studies [@pone.0082773-Higgins1], [@pone.0082773-Higgins2]. If the result of the *Q* test was *P~Q~* \<0.1 or *I^2^*≥50%, indicating the presence of heterogeneity, a random-effects model (the DerSimonian and Laird method) was used to estimate the summary ORs [@pone.0082773-DerSimonian1]; otherwise, when the result of the *Q* test was *P~Q~* ≥0.1 and *I^2^*\<50%, indicating the absence of heterogeneity, the fixed-effects model (the Mantel--Haenszel method) was used [@pone.0082773-Mantel1]. To explore the sources of heterogeneity among studies, we performed logistic metaregression and subgroup analyses. The following study characteristics were included as covariates in the metaregression analysis: genotyping methods (PCR-RFLP versus not PCR-RFLP), ethnicity (Caucasian population versus Asian population), quality score (high quality studies versus low quality studies), source of controls (Hospital-based versus Population-based), QC when genotyping (Yes versus no), and HCC confirmation (pathologically or histologically confirmed versus other diagnosis criteria). Subgroup analyses were conducted by ethnicity and hepatitis virus infection status. Galbraith plots analysis was performed for further exploration of the heterogeneity.

Sensitivity analysis was performed by sequential omission of individual studies. For each polymorphism, publication bias was evaluated using Begg's funnel plot and Egger's regression asymmetry test [@pone.0082773-Egger1]. The HWE of the control population in each eligible study was tested using a goodness-of-fit Chi-square test. All analyses were performed using Stata software, version 12.0 (Stata Corp., College Station, TX). All *p* values were two-sided. To ensure the reliability and the accuracy of the results, two authors entered the data into the statistical software programs independently with the same results.

Results {#s3}
=======

Study Characteristics {#s3a}
---------------------

Based on our search criteria, 25 studies relevant to the role of TP53 R72P and/or MDM2 SNP309 on HCC susceptibility were identified. Six of these articles were excluded including 3 publications containing overlapping data [@pone.0082773-Zhu1]--[@pone.0082773-Ezzikouri1], and 3 were meta-analyses [@pone.0082773-Ma1], [@pone.0082773-Lv1], [@pone.0082773-Ding1]. Manual search of references cited in the published studies did not reveal any additional articles. As a result, a total of 19 relevant studies including 16 English articles [@pone.0082773-Tomoda1], [@pone.0082773-Yang1], [@pone.0082773-Zhu2], [@pone.0082773-Akkiz1]--[@pone.0082773-Son1] and 3 Chinese papers (one was a dissertation of postgraduate student) [@pone.0082773-Jiang1], [@pone.0082773-Zhang1], [@pone.0082773-Peng1] met the inclusion criteria for the meta-analysis ([Figure S1](#pone.0082773.s001){ref-type="supplementary-material"}). The main characteristics of the studies were presented in [Table 2](#pone-0082773-t002){ref-type="table"}. Among them, 5 studies evaluated the MDM2 SNP309 polymorphism, 9 studies evaluated the TP53 R72P polymorphism, and 5 studies evaluated TP53 R72P and MDM2 SNP309 simultaneously. Therefore, a total of 10 studies including 2,243 cases and 3,615 controls were available for the meta-analysis of MDM2 SNP309 polymorphism and 14 studies containing 4,855 cases and 6,630 controls were included for TP53 R72P polymorphism. The sample size in these studies varied considerably, ranging from 183 to 3,727 individuals. Of all the eligible studies, 2 were conducted in Caucasians, 7 were in Asians, and 1 was in Africans for MDM2 SNP309 polymorphism; 9 were conducted in Asians, 4 in Caucasians, and 1 was in Africans for TP53 R72P polymorphism. Three studies were population--based and 16 were hospital--based studies. Fourteen articles of all eligible studies used quality control when genotyping and 4 studies in the present meta-analysis did not provide definite criteria for the HCC diagnosis. Several genotyping methods were used, including PCR-RFLP, TaqMan assay, and MALDI-TOF. The genotype distributions of the controls in 2 studies were not consistent with HWE for MDM2 SNP309 polymorphism [@pone.0082773-Leu1], [@pone.0082773-Yoon1] and 2 were not consistent with HWE for TP53 R72P polymorphism [@pone.0082773-Sumbul1], [@pone.0082773-Yu1].

10.1371/journal.pone.0082773.t002

###### Characteristics of eligible studies.

![](pone.0082773.t002){#pone-0082773-t002-2}

  First author (Year)    Country   Ethnicity   Sample size (case/control)   Genotyping methods         Matching criteria          Source of control   HCC confirmation   QC when Genotyping             SNPs              HWE(*P* value)   Quality scores  
  --------------------- --------- ----------- ---------------------------- -------------------- -------------------------------- ------------------- ------------------ -------------------- --------------------------- ---------------- ---------------- ------
  Akkiz 2004             Turkey    Caucasian            110/110                  PCR-RFLP        Age, gender, smoking, drinking          PB                  HC                 Yes                  MDM2 SNP309              0.239              --          9
  Leu 2009                China      Asian               58/138                  PCR-RFLP                  Ethnicity                     HB                  NA                 Yes                  MDM2 SNP309            **0.048**            --          5
  Dharel 2006             Japan      Asian              187/296                TaqMan assay                 Drinking                     HB                  HC                 Yes                  MDM2 SNP309              0.724              --          7
  Ezzikouri 2011         Morocco    African              96/222                  PCR-RFLP                 Age, gender                    HB                  NA                 Yes           MDM2 SNP309, p53 Arg72Pro       0.508            0.685         4
  Tomoda 2012             Japan      Asian              258/199                 MALDI-TOF            Age, gender, drinking               HB                  HC                  No                  MDM2 SNP309              0.640              --          8
  Vuolo 2011              Italy    Caucasian             61/122                  PCR-RFLP                 Age, gender                    PB                  PC                  No           MDM2 SNP309, p53 Arg72Pro       0.127            0.428         7
  Wang 2012               China      Asian              310/794                  PCR-RFLP                 Age, gender                    HB                  HC                 Yes                  MDM2 SNP309              0.111              --          7
  Yoon 2008               Korea      Asian              287/296                  PCR-RFLP                    Gender                      HB                  HC                  No           MDM2 SNP309, p53 Arg72Pro     **0.063**          0.978         8
  Yang 2013               China      Asian              350/326                TaqMan assay                   Age                        HB                  PC                 Yes           MDM2 SNP309, p53 Arg72Pro       0.738            0.636         8
  Jiang 2008              China      Asian             1375/2352                 PCR-RFLP                 Age, gender                    HB                  PC                 Yes           MDM2 SNP309, p53 Arg72Pro       0.134            0.145         8
  Sumbul 2012            Turkey    Caucasian            119/119                  PCR-RFLP        Age, gender, smoking, drinking          HB                  HC                 Yes                 p53 Arg72Pro                --           **0.022**       9
  Leveri 2004             Italy    Caucasian             86/254                  PCR-RFLP                      NA                        HB                  HC                  No                 p53 Arg72Pro                --             0.301         6
  Yu 1999                 China      Asian               80/328                  PCR-RFLP              Smoking, drinking                 HB                  PC                 Yes                 p53 Arg72Pro                --           **0.019**       6
  Anzola 2003             Spain    Caucasian             97/111                  PCR-SSCP                    Region                      HB                  NA                  No                 p53 Arg72Pro                --             0.375         5
  Zhang 2012              China      Asian              985/992                TaqMan assay               Age, gender                    HB                  PC                 Yes                 p53 Arg72Pro                --             0.898         8
  Peng 2004               China      Asian              192/192                  PCR-RFLP            Age, gender, ethnicity              HB                  PC                 Yes                 p53 Arg72Pro                --             0.481         7
  Son 2013                Korea      Asian              157/201                  PCR-RFLP            Age, gender, drinking               HB                  NA                 Yes                 p53 Arg72Pro                --             0.086         7
  Xu 2011                 China      Asian              501/548                  PCR-RFLP             Age, gender, region                PB                  PC                 Yes                 p53 Arg72Pro                --             0.359         11
  Zhu 2005                China      Asian              469/567                  PCR-RFLP              Smoking, drinking                 HB                  HC                 Yes                 p53 Arg72Pro                --             0.321        8.25

SNP, Single nucleotide polymorphism; HC, Histologically confirmed; PC, Pathologically confirmed; NA, Not available; QC, Quality control; PB, Population--based; HB, Hospital--based; HWE, Hardy--Weinberg equilibrium in control population; PCR--RFLP, Polymerase chain reaction-restriction fragment length polymorphism; MALDI-TOF, Matrix-assisted laser desorption/ionization-time of flight mass spectrometry; PCR-SSCP, Polymerase chain reaction-single strand conformation polymorphism.

Meta-analysis Results {#s3b}
---------------------

[Table 3](#pone-0082773-t003){ref-type="table"} lists the main results of this meta-analysis.

10.1371/journal.pone.0082773.t003

###### Summary of the meta-analysis results for MDM2 SNP309 and TP53 Arg72Pro polymorphisms and HCC risk.
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  Comparison                       Population        No. of studies   Test of association         Mode         Test of heterogeneity                       
  -------------------------- ---------------------- ---------------- --------------------- ------------------ ----------------------- ---- ------- ------- ------
  MDM2 SNP309                                                                                                                                              
  G vs. T                           Overall                10                1.371            1.153--1.631             0.000           R    39.11   0.000   77.0
                                   Caucasian               2                 1.987            1.488--2.653             0.000           F    0.01    0.907   0.0
                                     Asian                 7                 1.249            1.039--1.501             0.018           R    26.58   0.000   77.4
                                    African                1                 1.569            1.090--2.258             0.015           --    --      --      --
                                  HBV positive             4                 1.207            0.933--1.563             0.153           R    16.88   0.001   82.2
                                  HCV positive             3                 1.481            1.245--1.761             0.000           F    2.67    0.263   25.1
                              High quality studies         5                 1.467            1.284--1.674             0.000           F    3.47    0.483   0.0
  GG vs. TT                         Overall                10                1.831            1.300--2.579             0.001           R    34.56   0.000   74.0
                                   Caucasian               2                 3.604            1.991--6.524             0.000           F    0.00    0.974   0.0
                                     Asian                 7                 1.539            1.070--2.212             0.020           R    23.98   0.001   75.0
                                    African                1                 2.604            1.079--6.280             0.033           --    --      --      --
                                  HBV positive             4                 1.416            0.864--2.322             0.168           R    14.82   0.002   79.8
                                  HCV positive             3                 2.198            1.542--3.134             0.000           F    1.65    0.437   0.0
                              High quality studies         5                 2.096            1.567--2.803             0.000           F    2.39    0.665   0.0
  TG vs. TT                         Overall                10                1.416            1.126--1.780             0.003           R    20.48   0.015   56.1
                                   Caucasian               2                 2.433            1.509--3.922             0.000           F    0.26    0.613   0.0
                                     Asian                 7                 1.242            0.989--1.560             0.062           R    11.32   0.079   47.0
                                    African                1                 1.590            0.958--2.641             0.073           --    --      --      --
                                  HBV positive             4                 1.145            0.938--1.398             0.184           F    5.60    0.133   46.4
                                  HCV positive             3                 1.759            1.280--2.418             0.001           F    1.90    0.387   0.0
                              High quality studies         5                 1.571            1.225--2.014             0.000           F    2.97    0.562   0.0
  GG vs. TG+TT                      Overall                10                1.398            1.148--1.703             0.001           R    19.51   0.021   53.9
                                   Caucasian               2                 2.112            1.271--3.507             0.004           F    0.10    0.755   0.0
                                     Asian                 7                 1.298            1.053--1.601             0.015           R    1.20    0.977   0.0
                                    African                1                 2.081            0.897--4.827             0.088           --    --      --      --
                                  HBV positive             4                 1.244            0.932--1.661             0.139           R    9.51    0.023   68.5
                                  HCV positive             3                 1.507            1.147--1.980             0.003           F    0.94    0.626   0.0
                              High quality studies         5                 1.564            1.281--1.908             0.000           F    1.70    0.791   0.0
  GG+TG vs. TT                      Overall                10                1.577            1.209--2.058             0.001           R    31.08   0.000   71.0
                                   Caucasian               2                 2.734            1.743--4.289             0.000           F    0.14    0.704   0.0
                                     Asian                 7                 1.377            1.036--1.830             0.028           R    19.71   0.003   69.6
                                    African                1                 1.719            1.058--2.794             0.029           --    --      --      --
                                  HBV positive             4                 1.289            0.883--1.881             0.188           R    11.31   0.010   73.5
                                  HCV positive             3                 1.926            1.426--2.601             0.000           F    2.09    0.352   4.2
                              High quality studies         5                 1.765            1.394--2.235             0.000           F    2.70    0.610   0.0
  p53 Arg72Pro                                                                                                                                             
  Pro vs. Arg                       Overall                14                1.045            0.938--1.164             0.424           R    38.51   0.000   66.2
                                   Caucasian               4                 1.105            0.897--1.362             0.347           F    4.43    0.218   32.3
                                     Asian                 9                 1.017            0.899--1.151             0.788           R    30.97   0.000   74.2
                                    African                1                 1.330            0.911--1.941             0.140           --    --      --      --
                                  HBV positive             7                 1.041            0.856--1.267             0.686           R    27.03   0.000   77.8
                                  HCV positive             3                 0.957            0.721--1.270             0.759           F    0.32    0.851   0.0
                              High quality studies         7                 1.106            0.964--1.270             0.151           R    26.86   0.000   77.7
  ProPro vs. ArgArg                 Overall                14                1.132            0.887--1.446             0.319           R    43.70   0.000   70.2
                                   Caucasian               4                 1.454            0.864--2.446             0.159           F    4.85    0.183   38.2
                                     Asian                 9                 1.044            0.805--1.356             0.744           R    33.12   0.000   75.8
                                    African                1                 2.304            0.954--5.234             0.046           --    --      --      --
                                  HBV positive             7                 1.159            0.751--1.789             0.506           R    31.95   0.000   81.2
                                  HCV positive             3                 1.169          0.606**--**2.255           0.640           F    0.43    0.805   0.0
                              High quality studies         7                 1.285            0.934--1.768             0.123           R    33.80   0.000   82.2
  ArgPro vs. ArgArg                 Overall                14                1.023            0.938--1.114             0.611           F    17.77   0.166   26.9
                                   Caucasian               4                 0.984            0.743--1.302             0.907           F    3.82    0.282   21.5
                                     Asian                 9                 1.017            0.889--1.162             0.810           R    13.83   0.086   42.2
                                    African                1                 0.973            0.576--1.647             0.920           --    --      --      --
                                  HBV positive             7                 0.957            0.845--1.083             0.483           F    10.38   0.110   42.2
                                  HCV positive             3                 0.802            0.545--1.180             0.262           F    0.04    0.980   0.0
                              High quality studies         7                 1.061            0.964--1.167             0.228           F    4.64    0.591   0.0
  ProPro vs. ArgPro+ArgArg          Overall                14                1.129            0.909--1.402             0.273           R    43.69   0.000   70.2
                                   Caucasian               4                 1.561            0.946--2.574             0.081           F    5.36    0.148   44.0
                                     Asian                 9                 1.041            0.835--1.297             0.721           R    31.06   0.000   74.2
                                    African                1                 2.327            0.949--5.162             0.038           --    --      --      --
                                  HBV positive             7                 1.202            0.812--1.780             0.357           R    32.67   0.000   81.6
                                  HCV positive             3                 1.291            0.684--2.437             0.430           F    0.43    0.807   0.0
                              High quality studies         7                 1.223            0.915--1.635             0.174           R    37.19   0.000   83.9
  ProPro+ArgPro vs. ArgArg          Overall                14                1.032            0.912--1.167             0.619           R    23.41   0.037   44.5
                                   Caucasian               4                 1.040            0.795--1.361             0.774           F    3.69    0.297   18.7
                                     Asian                 9                 1.020            0.878--1.184             0.799           R    19.36   0.013   58.7
                                    African                1                1.174.            0.725--1.900             0.515           --    --      --      --
                                  HBV positive             7                 0.980            0.790--1.215             0.852           R    14.70   0.023   59.2
                                  HCV positive             3                 0.855            0.594--1.233             0.402           F    0.14    0.932   0.0
                              High quality studies         7                 1.056            0.964--1.156             0.240           F    9.70    0.138   38.1

OR, odds ratio; CI, confidence intervals; R, random effects model; F, fixed effects model; PB, Population--based; HB, Hospital--based.

For the MDM2 SNP309 polymorphism, the between-study heterogeneity was significant when all 10 studies were pooled into meta-analysis (I^2^\>50.0%, or P~Q~ \<0.10), thus, the random-effects model was used to pool the results. The results of pooling all studies showed that the MDM2 SNP309 polymorphism was associated with increased HCC risk in all genetic models (G vs. T: OR = 1.371, 95%CI: 1.153--1.631, P = 0.000; GG vs. TT: OR = 1.831, 95%CI: 1.300--2.579, P = 0.001, [Figure 1](#pone-0082773-g001){ref-type="fig"}; TG vs. TT: OR = 1.416, 95%CI: 1.126--1.780, P = 0.003; GG vs. TG+TT: OR = 1.398, 95%CI: 1.148--1.703, P = 0.001; GG+TG vs. TT: OR = 1.577, 95%CI: 1.209--2.058, P = 0.001). In subgroup analyses by ethnicity, the results showed that the MDM2 SNP309 polymorphism was associated with increased HCC risk in Asians (G vs. T: OR = 1.249, 95%CI: 1.039--1.501, P = 0.018; GG vs. TT: OR = 1.539, 95%CI: 1.070--2.212, P = 0.020; GG vs. TG+TT: OR = 1.298, 95%CI: 1.053--1.601, P = 0.015; GG+TG vs. TT: OR = 1.377, 95%CI: 1.036--1.830, P = 0.028), Caucasians (G vs. T: OR = 1.987, 95%CI: 1.488--2.653, P = 0.000; GG vs. TT: OR = 3.604, 95%CI: 1.991--6.524, P = 0.000; TG vs. TT: OR = 2.433, 95%CI: 1.509--3.922, P = 0.000; GG vs. TG+TT: OR = 2.112, 95%CI: 1.271--3.507, P = 0.004; GG+TG vs. TT: OR = 2.734, 95%CI: 1.743--4.289, P = 0.000), and Africans (G vs. T: OR = 1.569, 95%CI: 1.090--2.258, P = 0.015; GG vs. TT: OR = 2.604, 95%CI: 1.079--6.280, P = 0.033; GG+TG vs. TT: OR = 1.719, 95%CI: 1.058--2.794, P = 0.029). In subgroup analysis by hepatitis virus infection status, the results showed that the MDM2 SNP309 polymorphism was associated with increased HCC risk in HCV positive patients (G vs. T: OR = 1.481, 95%CI: 1.245--1.761, P = 0.000; GG vs. TT: OR = 2.198, 95%CI: 1.542--3.134, P = 0.000; TG vs. TT: OR = 1.759, 95%CI: 1.280--2.418, P = 0.001; GG vs. TG+TT: OR = 1.507, 95%CI: 1.147--1.980, P = 0.003; GG+TG vs. TT: OR = 1.926, 95%CI: 1.426--2.601, P = 0.000) but not in HBV positive subjects.

![Subgroup analysis by ethnicity in the meta-analysis on the association between MDM2 SNP309 polymorphism and HCC risk using a random-effect model (additive model GG vs. TT).](pone.0082773.g001){#pone-0082773-g001}

For the TP53 R72P polymorphism, the between-study heterogeneity was also significant when all 14 eligible studies were pooled into meta-analysis (I^2^\>50.0%, or P~Q~ \<0.10), thus the random-effects model was used to pool the results. The meta-analysis results showed that the TP53 R72P polymorphism was not associated with increased HCC risk in the overall populations. In the stratified analyses by ethnicity and hepatitis virus infection status, statistically significant associations were also not observed in all subgroups ([Figure 2](#pone-0082773-g002){ref-type="fig"}).

![Subgroup analysis by ethnicity in the meta-analysis on the association between TP53 Arg72Pro polymorphism and HCC risk using a random-effect model (additive model ProPro vs. ArgArg).](pone.0082773.g002){#pone-0082773-g002}

For the MDM2 SNP309--TP53 R72P interaction analysis, the between-study heterogeneity was not significant in most of subgroups when all three eligible studies were pooled into meta-analysis (I^2^≤50.0%, and P~Q~ \>0.10; [Table 4](#pone-0082773-t004){ref-type="table"}), thus the fix-effects model was used to pool the results. In comparison to the reference MDM2 309TT and p53 Arg/Arg genotype, subjects with the MDM2 309TT and TP53 Pro/Pro genotype (OR = 1.996, 95%CI: 1.076--3.700, P = 0.028), MDM2 309 TG and TP53 Arg/Pro genotype (OR = 1.627, 95%CI: 1.110--2.385, P = 0.013), and MDM2 309 GG and TP53 Pro/Pro genotype (OR = 5.237, 95%CI: 2.845--9.639, P = 0.000) present significantly higher risk of developing HCC. However, no any dose-effect relationship was found between the MDM2 SNP309 and TP53 R72P polymorphisms on HCC risk.

10.1371/journal.pone.0082773.t004

###### Summary odds ratios with confidence intervals for joint effect of MDM2 SNP309 and TP53 R72P polymorphisms on HCC risk.

![](pone.0082773.t004){#pone-0082773-t004-4}

  TP53 Arg72Pro    MDM2 SNP309   No. of studies   Test of association       Mode       Test of heterogeneity                      
  --------------- ------------- ---------------- --------------------- -------------- ----------------------- ---- ------ ------- ------
  Arg/Arg              TT              3               Reference             --                 --             --    --     --    
                       TG              3                 1.996          1.076--3.700           0.028           F    1.92   0.382   0.0
                       GG              3                 1.674          0.770--3.641           0.194           R    5.11   0.078   60.8
  Arg/Pro              TT              3                 1.066          0.693--1.639           0.771           F    1.63   0.442   0.0
                       TG              3                 1.627          1.110--2.385           0.013           F    0.89   0.639   0.0
                       GG              3                 1.315          0.827--2.090           0.247           F    0.85   0.655   0.0
  Pro/Pro              TT              3                 1.996          1.076--3.700           0.028           F    1.92   0.382   0.0
                       TG              3                 1.462          0.882--2.422           0.141           F    0.45   0.798   0.0
                       GG              3                 5.237          2.845--9.639           0.000           F    3.56   0.169   43.8

*P~Q~,* P value of Q-test for heterogeneity test; R, random-effects model, F, fixed-effects model.

Heterogeneity Analysis {#s3c}
----------------------

For the MDM2 SNP309 polymorphism, the *I^2^* values of heterogeneity were greater than 50% and the *P~Q~* values were lower than 0.10 in all genetic comparison models (additive model GG vs. TT and TG vs. TT, recessive model GG vs. TG+TT, and dominant model GG+TG vs. TT) in the overall populations, which indicated statistically significant heterogeneity among studies. To explore the sources of heterogeneity, we performed metaregression and subgroup analyses. Metaregression analysis of data showed that the ethnicity and Quality scores were the major sources which contributed to heterogeneity (regression coefficient = 0.114, 95%CI: 0.075--0.153, p = 0.003 for ethnicity and regression coefficient = 0.217, 95%CI: 0.093--0.341, p = 0.016 for Quality scores, respectively). The Genotyping methods, HCC confirmation, Source of control, and QC when genotyping were not effect modifiers. Subsequently, we performed subgroup analyses by ethnicity and hepatitis virus infection status. However, heterogeneity still existed in all the above genetic comparison models in Asians and HBV positive subgroup ([Table 3](#pone-0082773-t003){ref-type="table"}). To further investigate the heterogeneity, we performed Galbraith plots analysis to identify the outliers which might contribute to the heterogeneity. Our results showed that the studies Jiang et al. [@pone.0082773-Jiang1] and Yang et al. [@pone.0082773-Yang1] were outliers in all the above four genetic comparison models in the overall populations ([Figure 3](#pone-0082773-g003){ref-type="fig"}). All *I^2^* values decreased obviously and *P~Q~* values were greater than 0.10 after excluding the two studies Jiang et al. [@pone.0082773-Jiang1] and Yang et al. [@pone.0082773-Yang1] in all genetic comparison models in the overall populations, Asians and HBV positive subgroup. However, the significance of the summary ORs for the MDM2 SNP309 polymorphism in different comparison models in the overall populations, Asians and HBV positive subgroup were not influenced by omitting the two studies (Data not shown).

![Galbraith plots of MDM2 SNP309 polymorphism and HCC risk (additive model GG vs. TT).\
The studies of Jiang et](pone.0082773.g003){#pone-0082773-g003}

For the TP53 R72P polymorphism, significant between-study heterogeneity was also observed in the pooling analyses of total available studies (the *I^2^* values of heterogeneity were greater than 50% and the *P~Q~* values were lower than 0.10 for additive model ProPro vs. ArgArg, recessive model ProPro vs. ArgPro+ArgArg, and dominant model ProPro+ArgPro vs. ArgArg). Metaregression analysis showed that the Quality scores was the major source heterogeneity (regression coefficient = 0.127, 95%CI: 0.051--0.203, p = 0.001). The Ethnicity, Genotyping methods, HCC confirmation, Source of control, and QC when genotyping were not effect modifiers. Galbraith plots analysis indicated that the studies by Jiang et al. [@pone.0082773-Jiang1] and Yoon et al. [@pone.0082773-Yoon1] were spotted as the major source of the heterogeneity ([Figure 4](#pone-0082773-g004){ref-type="fig"}). The *I^2^* values decreased obviously and *P~Q~* values were greater than 0.10 after excluding the two studies Jiang et al. [@pone.0082773-Jiang1] and Yoon et al. [@pone.0082773-Yoon1] in the overall populations, Asians and HBV positive subgroup. However, the significance of the ORs for the TP53 R72P polymorphism in the overall populations, Asians and HBV positive subgroup were also not changed by excluding the two studies.

![Galbraith plots of TP53 Arg72Pro polymorphism and HCC risk (additive model ProPro vs. ArgArg).\
The studies of Jiang et](pone.0082773.g004){#pone-0082773-g004}

Sensitivity Analysis {#s3d}
--------------------

Sensitivity analysis was performed by sequential omission of individual studies for both MDM2 SNP309 and TP53 R72P polymorphisms. For analyses of pooling more than three individual studies, the significance of ORs was not influenced excessively by omitting any single study (data not shown). For the MDM2 SNP309 polymorphism, sensitivity analysis was further performed by omitting the studies by Leu et al. [@pone.0082773-Leu1] and Yoon et al. [@pone.0082773-Yoon1] in which the control populations were not in accordance with HWE. The significance of all ORs was not altered after excluding these two studies. For the TP53 R72P polymorphism, a sensitivity analysis was also further performed by omitting those two studies by Sumbul et al. [@pone.0082773-Sumbul1] and Yu et al. [@pone.0082773-Yu1] in which the control populations were deviated from HWE, and the significance of all ORs was also not altered.

Publication Bias {#s3e}
----------------

Begg's funnel plot and Egger's test were performed to access the publication bias in this meta-analysis. Funnel plot shapes did not reveal obvious evidence of asymmetry, and all the p values of Egger's tests were more than 0.05 for both MDM2 SNP309 and TP53 R72P polymorphisms, providing statistical evidence of the funnel plots' symmetry ([Figure S2](#pone.0082773.s002){ref-type="supplementary-material"}). The results suggested that publication bias was not evident in this meta-analysis.

Discussion {#s4}
==========

Previous studies investigating the associations between MDM2 SNP309 and/or TP53 R72P polymorphisms and HCC risk have provided inconsistent results, and most of those studies involved no more than a few hundred HCC cases, which is too few to assess any genetic effects reliably. Meta-analysis has been recognized as an important tool to more precisely define the effect of selected genetic polymorphisms on the risk for disease and to identify potentially important sources of between-study heterogeneity. Hence, we performed this meta-analysis including all available studies to provide the most comprehensive assessment of the associations between the MDM2 SNP309 and TP53 R72P polymorphisms and HCC risk. Our results suggested that the MDM2 SNP309 polymorphism was significantly associated with increased HCC risk in the overall populations, different ethnic subgroups, and HCV positive patients. However, our data did not support a genetic association between the TP53 R72P polymorphism and HCC risk. In the MDM2 SNP309--TP53 R72P interaction analysis, we found that individuals with MDM2 309TT and TP53 Pro/Pro genotype, MDM2 309 TG and TP53 Arg/Pro genotype, and MDM2 309 GG and TP53 Pro/Pro genotype had significantly increased HCC risk compared to those with the reference MDM2 309TT and TP53 Arg/Arg genotype.

Acting as a tumor suppressor, TP53 could lead to cell growth arrest and/or apoptosis in response to DNA damage and other cellular stresses [@pone.0082773-Meek1]. The TP53 function is controlled by MDM2, which binds to TP53 and prevents TP53-dependent cell cycle arrest or apoptosis [@pone.0082773-Arva1]. On the other hand, the MDM2 promoter is regulated by TP53 [@pone.0082773-Barak1]. The functional TP53 Arg72Pro polymorphism has been shown to depress the activities of TP53 in inducing apoptosis, cell cycle arrest, and DNA repair [@pone.0082773-Orsted1], [@pone.0082773-Siddique1]. However, in the present meta-analysis, we found that TP53 R72P polymorphism was not significantly associated with the risk of HCC neither in the overall combined analysis nor the stratified analyses according to ethnicity and hepatitis virus infection status, which was inconsistent with the previous meta-analysis conducted by Lv et al. [@pone.0082773-Lv1] and Ding et al. [@pone.0082773-Ding1]. The main factor that would contribute to the discrepancy is that the previous meta-analyses with relatively small sample size may have insufficient statistical power to detect a real association with HCC risk or may have generated a fluctuated risk estimate. This observation is not a surprise because the TP53 72Pro allele could induce cell cycle arrest and DNA repair more efficiently to prevent transformation of normal cells [@pone.0082773-Orsted1].

MDM2 is one of the central nodes in the TP53 pathway. The proper regulation of MDM2 levels has been shown to be vital for TP53 tumor suppression, and even a modest change in levels could affect the TP53 pathway and, subsequently, cancer development in mouse models [@pone.0082773-Bond2]. The study by Bond et al. [@pone.0082773-Bond3] revealed that SNP309 GG cell lines expressed higher levels of MDM2 (on average 8-fold mRNA and 4-fold protein levels) than TT cell lines, whereas intermediate protein levels (on average 1.9-fold) were observed in heterozygous (TG) cell lines. Furthermore, Hong et al. [@pone.0082773-Hong2] showed that SNP309 GG carriers had significantly higher MDM2 mRNA expression in esophageal tissue than TT carriers, but the TG heterozygote did not confer an increased MDM2 transcription. Thus, there is obvious biological evidence for the effects of MDM2 SNP309 polymorphism on HCC risk. In the present meta-analysis, we found that the MDM2 SNP309 polymorphism was significantly associated with increased HCC risk in the overall populations, different ethnic subgroups, and HCV positive patients. This functional relevance of MDM2 SNP309 polymorphism is consistent with the molecular epidemiological finding, demonstrating that the MDM2 SNP309 polymorphism played an important role in the HCC development.

HBV belongs to a family of DNA viruses called hepadnaviruses. The oncogenic potential of HBV has been attributed to its ability to integrate into host cellular DNA, which, may activate neighboring cellular genes directly to offer a selective growth advantage to the liver cells. In addition, production of hepatitis B x (HBx) protein can act as a transactivator on various cellular genes for cell growth and tumorigenesis [@pone.0082773-Chan1]. In contrast, HCV is a positive-stranded RNA virus the genome of which does not seem to integrate into hepatocyte's genome [@pone.0082773-Castello1]. Therefore, differences in carcinogenetic mechanisms between these viruses may affect HCC development. In the present meta-analysis, we found that the MDM2 SNP309 polymorphism was significantly associated with increased HCC risk in HCV positive patients but not in HBV positive subgroup, which is consistent with the study conducted by Dharel et al. [@pone.0082773-Dharel1]. The explanation for preferentially increased HCC risk of MDM2 SNP309 polymorphism in HCV positive patients but not in HBV positive subgroup is that the TP53 function in the HCV patients could have been indirectly suppressed by the heightened MDM2 levels, making them more vulnerable to cancer development.

Previous research has demonstrated an interaction between MDM2 and TP53 at the molecular level [@pone.0082773-Chen1], and the combined effects of MDM2 SNP 309 and TP53 Arg72Pro have been examined in lung cancer, Li--Fraumeni syndrome and non-polyposis colorectal cancer, with conflicting results [@pone.0082773-Zhang2], [@pone.0082773-Talseth1], [@pone.0082773-Lind1]. In the present meta-analysis, we included all available three studies to explore the interaction effects between TP53 Arg72Pro and MDM2 SNP309 polymorphisms on HCC risk. We found that subjects with the MDM2 309TT and TP53 Pro/Pro genotype, MDM2 309 TG and TP53 Arg/Pro genotype, and MDM2 309 GG and TP53 Pro/Pro genotype present significantly increased risk of developing HCC as compared with the reference MDM2 309TT and TP53 Arg/Arg genotype. However, no any dose-effect relationship was found in the interaction analysis. To the best of our knowledge, this is the first meta-analysis to explore the combined effects of MDM2 SNP 309 and TP53 Arg72Pro polymorphisms on HCC risk. These results suggested a possible interaction effect between the MDM2 309GG and the TP53 72 Pro/Pro genotype in increasing the risk of HCC carcinogenesis.

Heterogeneity is a potential problem when interpreting the results of a meta-analysis, and finding the sources of heterogeneity is one of the most important goals of meta-analysis [@pone.0082773-Ioannidis1]. In the present meta-analysis, significant between-study heterogeneity in the pooled analyses of total eligible studies was observed (*P~Q~* values for MDM2 SNP 309 and TP53 Arg72Pro polymorphisms were all less than 0.10, and *I^2^* values were larger than 50.0%). To find the sources of heterogeneity, we performed subgroup analyses and. Subgroup analyses showed that the heterogeneity was still significant in Asians and HBV positive patients, while it was removed in the other subgroups, indicating that heterogeneity might result from the inconsistency of effects across those included studies from Asian population and HBV positive patients. Metaregression analysis showed that the ethnicity and Quality scores were the major sources of heterogeneity for MDM2 SNP 309 polymorphism and the Quality scores was the major source heterogeneity for TP53 Arg72Pro polymorphism. Subsequently, we performed Galbraith plots to further investigate the heterogeneity. For the MDM2 SNP 309 polymorphism, Galbraith plots spotted 2 studies [@pone.0082773-Yang1], [@pone.0082773-Jiang1] as the outliers and the possible major sources of heterogeneity. For the TP53 Arg72Pro polymorphism, Galbraith plots also spotted 2 studies [@pone.0082773-Jiang1], [@pone.0082773-Yoon1] as the outliers and the possible major source of heterogeneity. Interestingly, the studies spotted as the outliers were all from Asian populations and HBV positive subgroup, which further confirmed that the inconsistency of effects across those studies from the above population might be the major sources of heterogeneity in this meta-analysis. When excluding the studies of Yang et al. [@pone.0082773-Yang1] and Jiang et al. [@pone.0082773-Jiang1] for MDM2 SNP 309 polymorphism and the studies of Jiang et al. [@pone.0082773-Jiang1] and Yoon et al. [@pone.0082773-Yoon1] for p53 Arg72Pro polymorphism, all *I^2^* values decreased lower than 50% and *P~Q~* values were larger than 0.10 in all genetic comparison models in the overall populations, Asians, and HBV positive subgroup. However, the summary ORs for the MDM2 SNP309 and TP53 Arg72Pro polymorphisms in different comparison models in the overall population and subgroup analyses were not material change by omitting the studies spotted as outliers, indicating that our results were robust and reliable.

Some possible limitations in this meta-analysis should be acknowledged. First, the overall outcomes were based on individual unadjusted ORs, whereas a more precise evaluation should be adjusted by potentially suspected factors including age, gender, smoking status, and environmental factors. Second, the controls were not uniformly defined. Although most of the controls were selected mainly from healthy populations, some had benign disease such as liver cirrhosis, HBsAg positive and so on. Therefore, non-differential misclassification bias was possible because these studies may have included the control populations who have different risks of developing HCC. Third, the number of studies included in the meta-analysis for African population was relatively small and there was only one study in the African group, which may lead to low statistical power and generated fluctuate estimation. Finally, gene--environment interactions were not addressed in this meta-analysis due to the lack of sufficient data. As is generally accepted, aside from genetic factors and chronic infection with HBV or HCV, exposure to aflatoxin B1, liver cirrhosis, and habitual alcohol abuse are major risk factors for HCC; however, we could not perform subgroup analyses based on these environmental exposures owing to the limited reported information on such associations in those included studies.

Despite these limitations, this meta-analysis suggests that the MDM2 SNP 309 polymorphism but not TP53 Arg72Pro variant is associated with increased risk of HCC. In addition, our findings further suggest that the combination of MDM2 SNP 309 and TP53 Arg72Pro genotypes confers higher risk to develop HCC. However, it is necessary to conduct large sample studies using standardized unbiased genotyping methods, homogeneous HCC patients and well-matched controls. Moreover, gene--environment interactions should also be considered in the analysis. Such studies taking these factors into account may eventually lead to better, comprehensive understanding of the association between these polymorphisms and HCC risk.
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